Description
Inhalation aerosols continue to be the basis for successful lung therapy for several diseases, with therapeutic strategies and the range of technology significantly evolving in recent years.
In response, this third edition takes a new approach to reflect the close integration of technology with its application. After briefly presenting the general considerations that apply to aerosol inhalation, the central section of the book uses the focus on disease and therapeutic agents to illustrate the application of specific technologies.
The final integrated strategies section draws the major points from the applications for disease targets and drug products.
Table of Contents
0. Introduction
Anthony J. Hickey and Heidi M. Mansour
Section 1 Fundamentals
- Physicochemical Properties of Respiratory Particles and Formulations
- Particle Deposition in the Respiratory Tract and the Effect of Respiratory Disease
- Mathematical Modeling of Inhaled Therapeutic Aerosol Deposition in the Respiratory Tract
- Lung transporters & absorption mechanisms in the lungs.
- Bioavailability of inhaled compounds.
- 3D models as tools for inhaled drug development.
- Overview of the delivery technologies for inhalation aerosols
- Neonatal & Pediatric Inhalation Drug Delivery
- Asthma
- Drug Delivery in Pulmonary Aspergillosis
- Lung Cancer Inhalation Therapeutics
- Inhaled Therapeutics in Chronic Obstructive Pulmonary Disease
- Cystic fibrosis infection & Biofilm Busters
- CURRENT AND FUTURE CFTR Therapeutics-
- Innate and Adaptive Barrier Properties of Airway Mucus
- Non-tuberculous mycobacteria (NTM)
- Inhalational Therapies for Non-CF Bronchiectasis
- Pulmonary Fibrosis,
- Therapeutics in Pulmonary Hypertension
- Respiratory distress syndrome,
- Surfactant Aerosol Therapy for nRDS and ARDS
- Fundamentals in Nasal Drug Delivery
- Inhaled therapeutics against TB: the promise of pulmonary treatment and prevention strategies in the clinic
- Inhaled medication: factors that affect lung deposition
- A Critical Perspective on Future developments based on the knowledge we have now
B. Shekunov
Dr. William Bennett
Jeffry Schroeter, Bahman Asgharian, and Julia Kimbell
Mohammed Ali Selo,, Hassan H. A. Al-Alak, Carsten Ehrhardt
L. Garcia-Contreras
Sally-Ann Cryan, Jennifer Lorigan, Cian O’Leary
Daniel F. Moraga-Espinoza, Ashlee D. Brunaugh, Silvia Ferrati, Lara A. Heersema, Matthew J. Herpin, Patricia P. Martins, Hairui Zhang, Hugh D. C. Smyth
Section 2 Applications, Influence of Lung Disease Pathophysiology on Aerosol Deposition, Inhaler Device Technique in Respiratory Disease, & Clinical Outcomes in Drug Performance Assessment
Ariel Berlinski
Omar Usmani
Sawittree Sahakijpijarn, Jay I. Peters, Robert O. Williams III
Rajiv Dhand
Tejas Sinha, Paul DeJulio and Philip Diaz
Jennifer Fiegel and Sachin Gharse
Marne C. Hagemeijer, Gimano D. Amatngalim and Jeffrey M. Beekman
Alison Schaefer, Samuel K. Lai
M. Ghadiri, P. M. Young, and D. Traini
Ashvini Damodaran, Dustin R. Fraidenburg, and Israel Rubinstein
Priya Muralidharan, Dr. Don Hayes, Jr, and Dr. Heidi M. Mansour
Maria F. Acosta, Don Hayes, Jr., Jeffrey R. Fineman, Jason X.-J. Yuan, Stephen M. Black, and Heidi M. Mansour
Heidi M. Mansour, Debra Droopad, and Julie G. Ledford
Donovan B. Yeates
Zachary Warnken, Yu jin Kim, Heidi M. Mansour, Robert O. Williams III, Hugh D.C. Smyth
Dominique N; Kunda, Nitesh K. Miller, Elliott K.; Muttil, Pavan
Section 3 Integrated strategies (reflecting combined elements from chapters 8-23):
Joy Conway
Tania F. Bahamondez-Canas, Jasmim Leal, Hugh D.C. Smyth
26. Ensuring Effectiveness and Reproducibility of Inhaled Drug Treatment
Anthony J Hickey
27. Conclusion
A.J. Hickey, and H.M. Mansour
